Improved diagnostic accuracy of pancreatic diseases with a combination of various novel serum biomarkers - Case control study from manipal teaching hospital, Pokhara, Nepal

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 2171-2174

  Farooqui, Mohammad Shamim ^a   Mittal, Ankush ^a   Poudel, Bibek ^a   Mall, Suhas Kumar ^a   Sathian, Brijesh ^a   Tarique, Mohammad ^b   Farooqui, Mohammad Hibban ^c  

^a MANIPAL COLLEGE OF MEDICAL SCIENCES   (Nepal)

^b Katihar Medical College   (India)

^c Department of ENT   (Saudi Arabia)

Author keywords

Nepal; Pancreatic diseases; Serum biomarkers

Indexed keywords

CA 19-9 ANTIGEN; HAPTOGLOBIN; HP PROTEIN, HUMAN; SERUM AMYLOID A; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BLOOD; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NEPAL; PANCREAS; PANCREAS DISEASE; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; CA-19-9 ANTIGEN; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HAPTOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEPAL; PANCREAS; PANCREATIC DISEASES; PROGNOSIS; SERUM AMYLOID A PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84872685270     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.2171     Document Type: Article

References (14)

1. Benson AB (2007). Adjuvant therapy for pancreatic cancer, one small step forward. JAMA, 297, 311-3.
2. Biran H, Friedman N, Neumann L, Pras M, Shainkin-Kestenbaum R (1999). Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. Clin Chem Lab Med, 37,381-3.
3. Boll DT, Merkle EM (2003). Differentiating a chronic hyperplastic mass from pancreatic cancer: a challenge remaining in multidetector CT of the pancreas. Eur Radiol, 13, 42-9.
4. Brand RE, Nolen BM, Zeh HJ, et al (2011). Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res, 17, 805-16.
5. Greenlee RT, Murray T, Bolden S, Wingo PA (2000). Cancer statistics, 2000. CA Cancer J Clin, 50, 7-33.
6. Katz MH, Hwang R, Fleming JB et al (2008). Tumor-node-metastasis staging ofpancreatic adenocarcinoma. CA Cancer J Clin, 58, 111-25.
7. Kushner I (1994). The acute phase response. Immunol Today, 15, 72-80.
8. Narisada M, Kawamoto S, Kuwamoto K, et al (2008). Identification of an inducible factor secreted by pancreatic cancer cell lines that stimulates the production of fucosylated haptoglobin in hepatoma cells. Biochem Biophys Res Commun, 377, 792-6.
9. Okuyama N, Ide Y, Nakano M, et al (2006). Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer, 118, 2803-8.
10. Owen JA, Better FC, Hoban J (1960). A simple method for the determination of serum haptoglobins. J ClinPathol, 13, 163-4.
11. Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R (2010). Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol, 24, 349-58.
12. Rocha ULJ, Sanchez AVM, Esquete PJ, et al (2007). Evaluation of the Bilio-Pancreatic Region Using Endoscopic Ultrasonography in Patients Referred with and without Abdominal Pain and CA 19-9 Serum Level Elevation. J Pancreas, 8, 191-7.
13. Sell LS (1990). Cancer markers of the 1990s. Clin Lab Med, 10, 1-37.
14. Shrikhande SV, Barreto G, Koliopanos A (2009). Pancreatic carcinogenesis: The impact of chronic pancreatitis and its clinical relevance. Indian J Cancer, 46, 288-96.